Effect of Losartan and Fish Oil on Plasma IL-6 and Mobility in Older Persons. The ENRGISE Pilot Randomized Clinical Trial
| Autor: | Christine K. Liu, Russell P. Tracy, Cynthia L. Stowe, Anne B. Newman, Jane A. Cauley, Walter T. Ambrosius, Roger A. Fielding, Mary M. McDermott, Christiaan Leeuwenburgh, Kristina H. Lewis, Michael P. Walkup, Daniel P. Beavers, Marco Pahor, Laura C. Lovato, Barbara Radziszewska, Stephen B. Kritchevsky, Jane Lu, Stephen D. Anton, Todd M. Manini, Michael E. Miller, Samuel S. Wu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Aging medicine.medical_specialty Angiotensin receptor Pilot Projects 030204 cardiovascular system & hematology Placebo Losartan law.invention 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial law Internal medicine Multicenter trial Fatty Acids Omega-3 medicine Humans Mobility Limitation Risk factor Aged Aged 80 and over Interleukin-6 business.industry Fish oil Confidence interval Walking Speed 030104 developmental biology The Journal of Gerontology: Medical Sciences Female Geriatrics and Gerontology business Angiotensin II Type 1 Receptor Blockers medicine.drug |
| Zdroj: | The Journals of Gerontology: Series A. 74:1612-1619 |
| ISSN: | 1758-535X 1079-5006 |
| DOI: | 10.1093/gerona/gly277 |
| Popis: | Background Low-grade chronic inflammation, characterized by elevations in plasma Interleukin-6 (IL-6), is an independent risk factor of impaired mobility in older persons. Angiotensin receptor blockers and omega-3 polyunsaturated fatty acids (ω-3) may reduce IL-6 and may potentially improve physical function. To assess the main effects of the angiotensin receptor blocker losartan and ω-3 as fish oil on IL-6 and 400 m walking speed, we conducted the ENRGISE Pilot multicenter randomized clinical trial. Methods The ENRGISE Pilot enrolled participants between April 2016 and June 2017, who participated for 12 months. Participants were aged ≥70 years with mobility impairment, had IL-6 between 2.5 and 30 pg/mL, and were able to walk 400 m at baseline. Participants were randomized in three strata 2 × 2 factorial to: (i) losartan 50–100 mg/d or placebo (n = 43), (ii) fish oil 1,400–2,800 mg/d or placebo (n = 180), and (iii) with both (n = 66). Results Two hundred eighty-nine participants were randomized (mean age 78.3 years, 47.4% women, 17.0% black). There was no effect of losartan (difference of means = −0.065 ± 0.116 [SE], 95% confidence interval [CI]: −0.293–0.163, p = .58) or fish oil (−0.020 ± 0.077, 95% CI: −0.171–0.132, p = .80) on the log of IL-6. Similarly, there was no effect of losartan (−0.025 ± 0.026, 95% CI: −0.076–0.026, p = .34) or fish oil (0.010 ± 0.017, 95% CI: −0.025–0.044, p = .58) on walking speed (m/s). Conclusions These results do not support the use of these interventions to prevent mobility loss in older adults at risk of disability with low-grade chronic inflammation. Registration Clinicaltrials.gov NCT02676466. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|